AU2013316100B8 - Antibody evolution immunogens - Google Patents

Antibody evolution immunogens Download PDF

Info

Publication number
AU2013316100B8
AU2013316100B8 AU2013316100A AU2013316100A AU2013316100B8 AU 2013316100 B8 AU2013316100 B8 AU 2013316100B8 AU 2013316100 A AU2013316100 A AU 2013316100A AU 2013316100 A AU2013316100 A AU 2013316100A AU 2013316100 B8 AU2013316100 B8 AU 2013316100B8
Authority
AU
Australia
Prior art keywords
ιιιιι
hiv
seq
composition
envelope protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013316100A
Other languages
English (en)
Other versions
AU2013316100A1 (en
AU2013316100B2 (en
Inventor
Scott Boyd
Feng Gao
Beatrice H. Hahn
Barton F. Haynes
Thomas B. Kepler
Bette T. Korber
Peter Kwong
Hua-Xin Liao
Rebecca M. Lynch
John Mascola
George M. Shaw
Tongqing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
University of Pennsylvania
Los Alamos National Security LLC
Duke University
Leland Stanford Junior University
United States Department of Health and Human Services
Original Assignee
Boston University
University of Pennsylvania
Los Alamos National Security LLC
Duke University
Leland Stanford Junior University
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, University of Pennsylvania, Los Alamos National Security LLC, Duke University, Leland Stanford Junior University, United States Department of Health and Human Services filed Critical Boston University
Publication of AU2013316100A1 publication Critical patent/AU2013316100A1/en
Assigned to DUKE UNIVERSITY, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, TRUSTEES OF BOSTON UNIVERSITY, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, LOS ALAMOS NATIONAL SECURITY, LLC, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reassignment DUKE UNIVERSITY Amend patent request/document other than specification (104) Assignors: DUKE UNIVERSITY, LOS ALAMOS NATIONAL SECURITY, LLC, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, TRUSTEES OF BOSTON UNIVERSITY
Publication of AU2013316100B2 publication Critical patent/AU2013316100B2/en
Application granted granted Critical
Publication of AU2013316100B8 publication Critical patent/AU2013316100B8/en
Priority to AU2018203805A priority Critical patent/AU2018203805A1/en
Assigned to LOS ALAMOS NATIONAL SECURITY, LLC, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, TRUSTEES OF BOSTON UNIVERSITY, DUKE UNIVERSITY, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA reassignment LOS ALAMOS NATIONAL SECURITY, LLC Request to Amend Deed and Register Assignors: DUKE UNIVERSITY, LOS ALAMOS NATIONAL SECURITY, LLC, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, TRUSTEES OF BOSTON UNIVERSITY
Priority to AU2020200453A priority patent/AU2020200453A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013316100A 2012-09-12 2013-09-12 Antibody evolution immunogens Active AU2013316100B8 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018203805A AU2018203805A1 (en) 2012-09-12 2018-05-30 Antibody Evolution Immunogens
AU2020200453A AU2020200453A1 (en) 2012-09-12 2020-01-22 Antibody evolution immunogens

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261700252P 2012-09-12 2012-09-12
US61/700,252 2012-09-12
US201261708466P 2012-10-01 2012-10-01
US61/708,466 2012-10-01
US201361764421P 2013-02-13 2013-02-13
US61/764,421 2013-02-13
PCT/US2013/000210 WO2014042669A1 (en) 2012-09-12 2013-09-12 Antibody evolution immunogens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203805A Division AU2018203805A1 (en) 2012-09-12 2018-05-30 Antibody Evolution Immunogens

Publications (3)

Publication Number Publication Date
AU2013316100A1 AU2013316100A1 (en) 2015-04-02
AU2013316100B2 AU2013316100B2 (en) 2018-03-01
AU2013316100B8 true AU2013316100B8 (en) 2018-03-08

Family

ID=50278581

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013316100A Active AU2013316100B8 (en) 2012-09-12 2013-09-12 Antibody evolution immunogens
AU2018203805A Abandoned AU2018203805A1 (en) 2012-09-12 2018-05-30 Antibody Evolution Immunogens
AU2020200453A Abandoned AU2020200453A1 (en) 2012-09-12 2020-01-22 Antibody evolution immunogens

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018203805A Abandoned AU2018203805A1 (en) 2012-09-12 2018-05-30 Antibody Evolution Immunogens
AU2020200453A Abandoned AU2020200453A1 (en) 2012-09-12 2020-01-22 Antibody evolution immunogens

Country Status (7)

Country Link
US (2) US10004800B2 (enExample)
EP (1) EP2895500B1 (enExample)
JP (1) JP6491095B2 (enExample)
CN (1) CN104968671B (enExample)
AU (3) AU2013316100B8 (enExample)
CA (1) CA2884859C (enExample)
WO (1) WO2014042669A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6491095B2 (ja) 2012-09-12 2019-04-03 デューク ユニバーシティ 抗体進化免疫原
US10149902B2 (en) 2014-03-19 2018-12-11 Duke University Swarm immunization with envelopes from CH505
CA2944068A1 (en) * 2014-03-31 2015-10-08 Duke University Compositions comprising ch848 envelopes and uses thereof
CA2962938A1 (en) * 2014-09-28 2016-03-31 Duke University Compositions comprising ch505 envelopes, and trimers
WO2016049633A1 (en) * 2014-09-28 2016-03-31 Duke University Compositions and methods for transient immune response modulation during vaccination
EP3240559A1 (en) * 2014-12-24 2017-11-08 Duke University Compositions comprising ch505 envelopes, and trimers (eight valent hiv-1 composition and methods)
WO2016172070A1 (en) * 2015-04-20 2016-10-27 Duke University Swarm immunization with envelopes from ch505
EP3423472A4 (en) 2016-03-01 2019-12-25 Duke University COMPOSITIONS WITH HIV COVERS FOR INDUCING CH235 CELL LINE ANTIBODIES
CA3016352A1 (en) 2016-03-03 2017-09-08 Duke University Compositions and methods for inducing hiv-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
WO2018218225A1 (en) 2017-05-25 2018-11-29 Duke University Compositions comprising modified hiv envelopes
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
WO2021081437A2 (en) 2019-10-23 2021-04-29 Duke University Compositions comprising v2 opt hiv envelopes
CA3202466A1 (en) 2021-01-14 2022-07-21 Jiani LI Hiv vaccines and methods of using
CA3206343A1 (en) 2021-01-28 2022-08-04 Rory HENDERSON Compositions comprising hiv envelopes to induce hiv-1 antibodies
EP4333614A4 (en) * 2021-05-05 2025-04-09 Leveragen, Inc. MANIPULATED NON-HUMAN ANIMALS TO PRODUCE ANTIBODIES
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
EP4415751A4 (en) * 2021-10-11 2025-10-08 Univ Duke Compositions containing HIV envelopes for the induction of HIV-1 antibodies
CA3234955A1 (en) * 2021-10-12 2023-04-20 Barton F. Haynes Compositions comprising v2 opt hiv envelopes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218817D0 (en) 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
AU2005280004B2 (en) * 2004-08-27 2012-02-23 Institute Of Tropical Medicine Modified HIV-1 envelope proteins
EP1802332A4 (en) * 2004-09-09 2010-08-18 Henry M Jackson Foundation MODIFIED HIV-1 CREAM PROTEINS
JP2006149234A (ja) 2004-11-25 2006-06-15 Japan Science & Technology Agency プライム−ブーストワクチン接種法
US8628782B2 (en) * 2009-02-26 2014-01-14 The United States Of America, As Represented By The Department Of Health And Human Services Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction
EP2477651A1 (en) 2009-09-17 2012-07-25 Sanofi Pasteur Inc. Immunological compositions for hiv
WO2011046623A2 (en) 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
EP2763699A4 (en) 2011-10-03 2015-05-20 Univ Duke VACCINE
JP6491095B2 (ja) 2012-09-12 2019-04-03 デューク ユニバーシティ 抗体進化免疫原

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009058989A1 (en) * 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines

Also Published As

Publication number Publication date
EP2895500A1 (en) 2015-07-22
JP2015529678A (ja) 2015-10-08
US10004800B2 (en) 2018-06-26
EP2895500B1 (en) 2019-11-27
WO2014042669A1 (en) 2014-03-20
US20180360948A1 (en) 2018-12-20
AU2020200453A1 (en) 2020-02-13
CA2884859A1 (en) 2014-03-20
AU2013316100B2 (en) 2018-03-01
US20150366961A1 (en) 2015-12-24
US10849970B2 (en) 2020-12-01
CN104968671A (zh) 2015-10-07
JP6491095B2 (ja) 2019-04-03
CN104968671B (zh) 2020-07-03
EP2895500A4 (en) 2016-04-13
AU2018203805A1 (en) 2018-06-21
CA2884859C (en) 2024-06-18

Similar Documents

Publication Publication Date Title
US10849970B2 (en) Antibody evolution immunogens
Liao et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Gorman et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
US11248027B2 (en) Engineered outer domain (eOD) of HIV GP120, mutants and use thereof
US9988424B2 (en) Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
US9738688B2 (en) HIV-1 envelope glycoprotein
Sabin et al. Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41
Burke et al. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens
Pan et al. Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans
US20200002383A1 (en) Compositions comprising hiv envelopes to induce ch235 lineage antibodies
US20200199204A1 (en) Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
van Eeden et al. V2-directed vaccine-like antibodies from HIV-1 infection identify an additional K169-binding light chain motif with broad ADCC activity
US10273291B2 (en) Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Banerjee et al. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region
Cook et al. Conformational plasticity of the HIV-1 gp41 immunodominant region is recognized by multiple non-neutralizing antibodies
Qin et al. Characterization of a large panel of rabbit monoclonal antibodies against HIV-1 gp120 and isolation of novel neutralizing antibodies against the V3 loop
EP3200824A1 (en) Swarm immunization with 54 envelopes from ch505
Cottrell Structure-based HIV immunogen design
Murrell Structural Evolution of Broadly Neutralizing Antibodies Against HIV During Natural Infection
Bhiman Defining Virus-Antibody Interplay During the Development of HIV-1 Neutralization Breadth to Inform Vaccine Design

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 8 , PAGE(S) 1153 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2013316100, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Free format text: IN VOL 29 , NO 16 , PAGE(S) 2344 UNDER THE HEADING CHANGE OF NAMES(S) OF APPLICANT(S), SECTION 104 - 2013 UNDER THE NAME DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, APPLICATION NO. 2013316100, UNDER INID (71) CORRECT THE CO-APPLICANT NAME TO THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: LOS ALAMOS NATIONAL SECURITY, LLC

Free format text: FORMER NAME(S): DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Owner name: TRUSTEES OF BOSTON UNIVERSITY

Free format text: FORMER NAME(S): DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Free format text: FORMER NAME(S): DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

Free format text: FORMER NAME(S): DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: FORMER NAME(S): DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

Owner name: DUKE UNIVERSITY

Free format text: FORMER NAME(S): DUKE UNIVERSITY; THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; LOS ALAMOS NATIONAL SECURITY, LLC; TRUSTEES OF BOSTON UNIVERSITY; THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES